-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Downgrades Outlook Therapeutics to Neutral

Benzinga·05/18/2026 10:23:30
Listen to the news
BTIG analyst Julian Harrison downgrades Outlook Therapeutics (NASDAQ:OTLK) from Buy to Neutral.